OpenAlex
PricingAboutJobs
Log inGet started
Work

ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

HTML

Year: 2020
Type: article
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.mct-19-1004
Authors: Lillian Skidmore, Sukumar Sakamuri, Nick A. Knudsen, Amha Gebre Hewet, Snezana Milutinovic, Wisam Barkho, Sandra Lyn Biroc, Jessica Kirtley, Robin Marsden, Kristine Storey, Ianina Lopez, Wayne Yu, Shiao-Yan Fang, Sulan Yao, Yi Gu, Feng Tian
Institution: Ambrx (United States)
Language: English

Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: antibody-drug conjugates, HER2-low breast cancer, HER2-positive breast cancer, gastric cancer, site-specific conjugation, drug-to-antibody ratio, ADC stability, patient-derived xenografts, cardiotoxicity
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3042830787
FWCI: 7.22
Cites: 42
Cited by: 176
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms